UROGEN PHARMA LTD's ticker is URGN and the CUSIP is M96088105. A total of 78 filers reported holding UROGEN PHARMA LTD in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $367,000 | 0.0% | 21,560 | -6.4% | 0.01% | +16.7% |
| Q2 2021 | $367,000 | -50.1% | 23,044 | -41.9% | 0.01% | -53.8% |
| Q1 2021 | $735,000 | +24.6% | 39,692 | +21.7% | 0.01% | 0.0% |
| Q4 2020 | $590,000 | +6.5% | 32,603 | +13.7% | 0.01% | -27.8% |
| Q3 2020 | $554,000 | -17.7% | 28,684 | +8.4% | 0.02% | -25.0% |
| Q2 2020 | $673,000 | +57.2% | 26,454 | +12.1% | 0.02% | +20.0% |
| Q1 2020 | $428,000 | -41.5% | 23,590 | +9.8% | 0.02% | -20.0% |
| Q4 2019 | $731,000 | +53.6% | 21,494 | +8.2% | 0.02% | +47.1% |
| Q3 2019 | $476,000 | -18.4% | 19,856 | +12.2% | 0.02% | -10.5% |
| Q2 2019 | $583,000 | +34.6% | 17,695 | +51.1% | 0.02% | -9.5% |
| Q1 2019 | $433,000 | -16.7% | 11,710 | -3.1% | 0.02% | -12.5% |
| Q4 2018 | $520,000 | +4.4% | 12,087 | +14.6% | 0.02% | +26.3% |
| Q3 2018 | $498,000 | +26.1% | 10,546 | +29.2% | 0.02% | -20.8% |
| Q1 2018 | $395,000 | +49.6% | 8,161 | +19.2% | 0.02% | +26.3% |
| Q4 2017 | $264,000 | – | 6,845 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 789,297 | $39,275,000 | 60.44% |
| Wildcat Capital Management, LLC | 251,459 | $12,513,000 | 9.57% |
| Consonance Capital Management LP | 1,487,491 | $74,018,000 | 4.77% |
| MENORA MIVTACHIM HOLDINGS LTD. | 2,499,870 | $124,394,000 | 3.53% |
| MEITAV INVESTMENT HOUSE LTD | 509,355 | $29,967,000 | 1.34% |
| DSAM Partners (London) Ltd | 127,588 | $6,349,000 | 1.28% |
| SHIKIAR ASSET MANAGEMENT INC | 48,125 | $2,395,000 | 1.00% |
| BANK HAPOALIM BM | 67,125 | $3,340,000 | 0.91% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 331,900 | $16,515,000 | 0.55% |
| Clal Insurance Enterprises Holdings Ltd | 310,000 | $15,426,000 | 0.40% |